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4-(Benzimidazolylmethyl)-1,2,3-triazole derivatives 8a-g and 9a-g have been developed using click chemistry protocol 
in regioselective manner and in high yields. These compounds have geometry to behave as chiral tweezers due to the 
presence of flexibly bound pi-rich hetero-aryl rings in addition to a chiral center. The synthesized chiral benzimidazole-
triazoles have been found to be useful as organocatalysts for the enantioselective Diels-Alder (DA) reaction between 
anthrone 10 and maleimide detivatives 11a-g. Enantioselectivity levels have been found to be dependent on several factors 
including nature of substituents in benzimidazole-triazoles 8a-g and 9a-g. 
Keywords: Enantiomerically enriched, click chemistry, tweezer, benzimidazole-triazoles, Diels-Alder adduct 
Amines work as efficient Lewis bases in many 
reactions. Chiral heterocyclic amines, with presence 
of one or more polar functional groups, have found 
applications in variety of asymmetric 
transformations1-9. Cinchona alkaloids, a classic 
example of such features, have exhibited applications 
in many chiral discriminative processes, such as 
asymmetric synthesis, kinetic resolutions, etc.10-15 
Chiral molecular recognition is yet another important 
process which requires similar structural features as 
multiple binding sites, presence of aryl/heteroaryl 
rings, presence of polar groups, etc.16a-d Though these 
types of molecules have shown efficient chiral 
discriminating abilities, the exact mechanistic 
requirement remains un-clear in most cases and hence 
it is generally very difficult to propose a chiral 
molecule as the best for a given purpose. This has 
necessitated availability of a large number of 
enantiomerically enriched molecules to suit the 
plethora of asymmetric transformations. 
Metal-based chiral catalysts17 have dominated the 
field of asymmetric catalysis for many decades. This 
catalytic system offers wide range of metals available 
for soft and hard chiral ligands. Metals ensure a better 
bound transition states resulting in better 
stereoselectivities. While organo-catalysis18 has to 
depend on multiple-ligating hetero-atoms or electron 
rich units such as presence of aryl groups for a rigid 
transition state species, needed for high levels of 
stereo-selections. There are some reports where 
excellent levels of stereoselections have been found, 
but in general, the results do not match the levels of 
chiral metal-based catalysis. Organo-catalysts 
however offer advantages such as cost effective, 
greener catalysis and less stringent reaction 
conditions. Therefore this continues to draw attention 
of the chiral community. 
Base-catalysed Diels–Alder reaction is unusual and 
works in a different manner; the base catalytically 
activates the diene to give a higher energy HOMO. 
The cycloadditions of anthrones and N-substituted 
maleimides are prominent examples of asymmetric 
catalysis exerted by chiral Brønsted bases, the 
resultant DA adduct α,β-butenolides and α,β-
unsaturated lactams have antipsoriatic and 
antiproliferative biological activities. However, many 
research groups, including our group, have developed 
the chiral base catalysed19,20a,b methodology with 
moderate to excellent enantioselectivity and good 
yield for DA adduct. Recently our group has 
employed benzimidazole based chiral tweezers18a for 
the asymmetric Diels-Alder reaction between 
anthrone and various maleimides; the methodology 
intriguingly gave reversal of enantioselectivity for 
obtained cyclo-adduct under the influence of different 
achiral part of the developed tweezers. 
In continuation of our quest in this area20a-e,21, we 
aimed to build a new chiral bi-heterocyclic system 
with benzimidazole-triazole as partners and its 
successful application as organocatalyst for the 
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enantioselective Diels-Alder (DA) reaction between 
anthrone and maleimide. 
 
Results and Discussion 
Philips condensation22 and Click chemistry 
protocols were employed for synthesis of desired 
tweezers. The copper(I)-mediated 1,3-dipolar 
cycloaddition of azides and terminal alkynes23 
(CuAAC) represents useful strategy for regioselective 
synthesis of 1,4-substituted 1,2,3-traizoles. The 
special feature of this reaction is high yield, mild 
conditions, environmentally friendly, and above all, a 
regiospecific outcome. 
Herein, we describe synthesis of new chiral 
benzimidazole tweezers namely N-1-((1-phenyl-1H-
1,2,3-triazol-4-yl)methyl)-(S)-(-)-2-(α-
hydroxyethyl/benzyl) benzimidazole (PT-HEB) 8a-g 
andN-1-((1-phenyl-1H-1,2,3-triazol-4-yl)methyl)-(S)-
(-)-2-(α-acetoxyethyl/benzyl) benzimidazole (PT-
AEB) 9a-g (Scheme I). (S)-2-(α-hydroxyethyl/benzyl) 
benzimidazole (HEB/HBB) 3a-b could be obtained 
from o-phenylenediamine (1) with respective (S)-
lactic acid/mandelic acid 2a-b24. Base-catalysed 
alkylation with propargyl bromide was carried out. 
Newly synthesized alkylated products 5a-b/6a-b 
exhibited C≡C-H band at 2110-2130 cm−1 and 
bridging CH2 group resonated at around δ 4.7 ppm as 
dd with a large coupling constant value (around18 
Hz) in 1H NMR. 
The alkylated chiral benzimidazoles 5a-b/6a-b 
serve as alkyne for click reaction. Aromatic azides 
could be synthesized from aromatic amines by 
diazotisation using reported procedure25. For synthesis 
of the benzimidazole-triazole tweezers click 
chemistry protocol, involving use of CuI-TEA in THF 
was employed, in a reaction between equimolar 
mixtures of alkylated chiral benzimidazoles 5a-b and 
substituted aromatic azides 7a-f at RT26. The N-1-((1-
Aryl-1H-1,2,3-triazol-4-yl)methyl)-(S)-(-)-2-(α-
hydroxyethyl) benzimidazole (PT-HEB) 8a-g was 
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Scheme I — Synthetic pathway for preparation of 8a-g and 9a-g 
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obtained as a fine white powder. The formation of 
compound 8a by 1,3-dipolar cyclo-addition was 
evident by the disappearance of a C≡C stretching 
band at 2117 cm−1 in IR and in 1H NMR the 
methylene protons at δ 5.78 was seen as dd with J 
value of 8.1 Hz, indicating clearly geminal coupling 
and diasterotopic nature of the methylene protons. 
Chiral identity was established for these 
cycloaddition products using normal phase HPLC and 
with use of Chiralpak IB as enantioselective 
stationary phase. The chiral tweezers with greater 
than 95% ee were obtained. Using the optimized 
reaction conditions, we next examined the scope and 
generality of this reaction with various types of 
substituted azides, and synthesized a small library of 
new chiral benzimidazole based triazoles 8a-f. The 
yield and enantiopurity of products were uniformly 
very high. (refer entry 1-6 of Table I) 
Based on our experience17c,d of better levels of 
chiral kinetic resolutions when acetyl derivatives 
rather than with free hydroxyls were employed 
involving chiral benzimidazoles, we decided to 
attempt similar strategy in the present investigations. 
Conversion of free hydroxyl group to their acetyl 
derivatives was therefore carried out to obtain N-1-
((1-aryl-1H-1,2,3-triazol-4-yl)methyl)-(S)-(-)-2-(α-
acetoxyethyl/benzyl) benzimidazole (PT-AEB) 9a-g 
with very high enantiomeric excess of >96% ee. 
The synthesized enantiopure heterocycle based 
tweezers 8a-e, 8g and 9a were then evaluated as the 
organo-catalysts, as Bronsted bases, for asymmetric 
Diels-Alder reaction of anthrone 10 and N-ethyl 
maleimide 11b at 0°C (Supporting Information 1.1). 
The organo bases 8a-e, 8g and 9a catalysed DA 
reaction gave good yields (83-91%), varied 
enantioselectivities (7-74% ee) and (S,S) 
configuration of Diels-Alder adduct. It was noticed 
that acetyl substituent on chiral centre (PT-AEB) 9a 
offered less enantioselectivity compared to free 
hydroxy group PT-HEB 8a. Substituents attached to 
phenyl ring at triazole seemed to be affecting steric 
and electronic properties and consequently differential 
enantioselectivities were found in different cases. 
Based on the overall better performance of catalyst 
PT-HEB 8a in the Diels-Alder reaction it was further 
selected for screening with regard to optimization of 
reaction conditions for the most suitable solvents and 
temperature. 
Furthermore, the systematic studies of Asymmetric 
Diels-Alder reaction PT-HEB 8a as an organo-
catalyst at RT in various solvents was carried out 
(Supporting Information 1.2). 1, 2-Dichloroethane 
(DCE) gave highest enantioselectivity with good 
conversion (89% yield, 37% ee), was selected as a 
best suitable solvent for the further screening of 
temperature. 
Optimal temperature of the DA reaction have been 
evaluated using PT-HEB 8a as an organo-catalyst at 
different temperatures in 1,2-Dichloroethane as a 
solvent (Supporting Information 1.3). On lowering the 
temperature of the reaction from RT to −10°C 
extended the reaction time yet furnished better 
enantioselectivities up to 83%. 
Under the optimized condition, we studied 
Asymmetric Diels-Alder reaction and anthrone 10 and 
various ranges of N-substituted maleimides 11a-g 
(Scheme II) and the results are listed in Table II. N-
alkyl substituted maleimides reacted smoothly giving 
 
 
Table II — Substrate scopes of antrone 10 and maleimide 11a-g 
for asymmetric Diels-Alder reaction 
Sr. 
No. 
N-Substituted 
Maleimide 11a-g 
DA Adduct 
12a-g 
Yield 
(%)b 
ee 
(%)c 
Configurationd 
1 CH3 (11a) 12a 86 57 (S, S) 
2 C2H5 (11b) 12b 82 83 (S, S) 
3 C3H7 (11c) 12c 84 5 (S, S) 
4 tert-Butyl (11d) 12d 82 28 (S, S) 
5 Benzyl (11e) 12e 75 61 (S, S) 
6 Ph (11f) 12f − − − 
7 p-OCH3Ph (11g) 12g − − − 
[a] All reactions were carried out using 0.5 mmol of N-alkyl/
aryl maleimide 11a-g, 0.5 mmol of anthrone 10 in 5 mL of 
1,2-dichlroethane at -10°C for 8-12 h. 
[b] Isolated yield after column chromatography. 
[c] Configuration was determined by optical rotation reported in 
literature19c-d,27. 
 
 
Table I — Substrate scope of chiral tweezer benzimidazole-
triazoles 8a-g and 9a-g 
Sr. No. Compd R R1 Yielda (%) [α]25D (°) ee b (%) 
1 8a CH3 H 78 +15 98 
2 8b CH3 o-Me 68 +13 98 
3 8c CH3 m-Me 75 +09 75 
4 8d CH3 p-Me 81 +22 100 
5 8e CH3 o-OMe 66 +24 95 
6 8f CH3 p-OMe 83 +16 97 
7 8g Ph H 82 − 98 
8 9a CH3 H 85 −97 99 
9 9b CH3 o-Me 82 −90 99 
10 9c CH3 m-Me 84 −86 99 
11 9d CH3 p-Me 83 −98 96 
12 9e CH3 o-OMe 80 −88 99 
13 9f CH3 p-OMe 87 −103 96 
14 9g Ph H 76 − 99 
[a] Represents isolated yield over three steps. 
[b] Determined by chiral HPLC analysis. 
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good yields (75-86%). But in case of N-aryl 
maleimides 11f-g, the desired cycloadducts could not 
be formed. Formation of Diels-Alder adducts 12a-e 
was confirmed by 1H NMR, and Mass Spectrum. 
The enantioselectivities (Table II) of these adducts 
12a-e were analysed by HPLC using chiral stationary 
phase. All N-alkyl substituted maleimides reacted 
smoothly giving good yields (75-86%) and mixed 
enantioselectivities (5-83% ee) (Table II, Entries 1-5). 
While with N-aryl maleimides 11f-g desired 
cycloadducts were not obtained. Excellent level of 
enantioselectivity was furnished with N-ethyl 
maleimide 11b upto 83% ee and 82 % yield (Table II, 
Entry 2). 
 
Plausible mechanism of asymmetric Diels-Alder 
reaction 
A plausible mechanism for this chiral base 
tweezers 8a-f, 9a catalysed Diels-Alder reaction of 
anthrone 10 and N-substituted maleimides 11a-e 
(Figure 1) is presented. It is proposed that the 
acidic proton of the anthrone was abstracted by the 
amine of triazole, converting anthrone to its 
dienolate form with protonated amine as its counter 
 
 
 
 
Scheme II — Substrate scopes of antrone 10 and maleimide 11a-g for asymmetric Diels-Alder reaction 
 
 
 
Figure 1 — A plausible mechanism for this chiral base tweezers 8a-f, 9a catalysed Diels-Alder reaction of anthrone 10 and N-substituted 
maleimides 11a-e 
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ion. The chiral catalyst with a hydroxyl group 
present at the chiral center then formed additional 
H-bond with the maleimide. Thus the chiral amine 
was partially bonded to the diene part and the 
dienophile part to induce stereoselectivity. In case 
of approach of the maleimide from the right hand 
side (S,S) configuration was expected, on the  
other hand in case the approach of the maleimide 
from the left hand side (R,R) configuration could  
be expected. 
The aromatic/heteroromatic methylene moiety 
attached to the ‘N’ of benzimidazole was believed to 
be in the same plane of the benzimidazole ring and 
was believed to be away from the side arm of the 
benzimidazole ring with a chiral center. This made the 
approach of the maleimide difficult from the left hand 
side and hence due to the approach of the maleimide 
from the right hand side the predominant enantiomer 
obtained was (S, S) for the adduct. 
 
Experimental Section 
All reagents and solvents of analytical grade were 
commercially available and used as received. The 
progress of the reaction was monitored by thin-layer 
chromatography (TLC) using silica gel of SDFCL 
Ltd. LR. 1H NMR, 13C NMR, COSY, NOESY, 
DEPT135 spectra were scanned in CDCl3 and DMSO-
d6 on Bruker (Avance II, 300MHz) spectrometers 
using TMS as an internal standard. IR spectra were 
recorded on Perkin-Elmer Frontier model. Optical 
rotations were recorded on Autopol IV-Ruldolph. 
Enantiomeric excess were determined by chiral HPLC 
analysis on Thermo Fisher spectra system UV1000 
HPLC unit. GC-MS spectra were recorded in Thermo 
Fisher Polaris Q-Trace GC Ultra. Melting points are 
uncorrected and were recorded on Mel-Temp melting 
point apparatus. 
 
General procedure for preparation of N-propargyl 
derivatives of benzimidazoles, 5, 6a-b 
(S)-2-(α-Hydroxyethyl/benzyl)benzimidazole 3a-b 
(24.5 mmol) or (S)-2-(α-acetoxy 
ethyl/benzyl)benzimidazole 4a-b and 24.5 mmol of 
propargyl bromide with 36.7 mmol of potassium 
carbonate (K2CO3) in round bottom flask was stirred 
at RT for 12 h. The course of reaction was monitored 
by Thin layer Chromatography (TLC). After complete 
disappearance of starting material the reaction 
mixture was poured in ice cold water. The obtained 
solid was filtered and air dried. 
 
General procedure for preparation of chiral 
benzimidazole based tweezers, 8a-g, 9a-g from 
alkylated benzimidazoles, 5, 6a-b 
CuI (9.52 mg, 0.050 mmol) and triethylamine 
(TEA) (0.021 g, 0.050 mmol) were stirred in THF 
(4.5 cc) at RT for 20 min, after which a homogeneous 
solution was obtained. 5a-b or 6a-b (1.00 mmol) and 
7a-f (0.201 g, 1.00 mmol) were dissolved in THF (5 
cc) and added in a single portion to the catalyst 
solution. The reaction mixture was allowed to stir for 
6-8 h, and then quenched by adding 10 cc of 10% 
NH4OH solution. A precipitate formed upon vigorous 
stirring and was isolated by filtration, as a fine white 
powder. 
 
Characterization data of chiral benzimidazole-
triazoles 8a-g and 9a-g 
N-1-((1-Phenyl-1H-1,2,3-triazol-4-yl)methyl)-
(S)-(-)-2-(α-hydroxy ethyl)benzimidazole (PT-
HEB), 8a: Yield 1.0 g (78%). m.p. 95°C. Specific 
rotation: [α]25D= +15° (c 1, Ethanol); 1H NMR (300 
MHz, MeOD): δ 1.76 (d, 3H, J = 4.2 Hz), 5.39 
(unresolved siglet, 1H), 5.78 (m, 2H, J = 8.1 Hz), 7.24 
(d, 2H, J = 6.6 Hz), 7.42-7.52 (m, 3H), 7.63-7.74 (m, 
4H), 8.42 (s,1H); 13C NMR (75 MHz, MeOD): δ 
21.90, 40.21, 64.22, 111.67, 119.92, 121.59, 122, 88, 
123.67, 124.41, 130.14, 130.90, 138.23, 145.48; GC-
MS: molecular ion (C18H17N5O) m/z value at 317.11. 
Anal. Calcd for C18H17N5O: С, 67.70; Н, 5.37; N, 
21.93. Found: С, 67.61; Н, 5.22; N, 22.12%. Chiral 
HPLC: Column: Chiralpak IB column of diacel, 
Solvent system: DCM (20% ethanol) /Hexane 25:75, 
Flow rate = 0.8 cc/min, λ = 250 nm), tmajor =15.24 
min, tminor =11.883 min, ee = 98%. 
N-(1-((1-(o-Tolyl)-1H-1,2,3-triazol-4-yl)methyl)-
(S)-(-)-2-(α-hydroxy ethyl) benzimidazole, 8b: 
Yield 0.86 g (68%). m.p. 75°C. Specific rotation: 
[α]D25 = +13° (c 1, Ethanol); 1H NMR (300 MHz, 
Acetone-d6): δ 1.75 (d, 3H, CH3, J = 5.7 Hz), 2.12 (s, 
3H, CH3), 5.44 (unresolved siglet, 1H), 5.76 (dd, 2H, 
J = 16.2 Hz ), 7.18-7.25 (m, 2H), 7.32-7.45 (m, 2H), 
7.65-7.70 (m, 3H), 8.28 (s, 1H); 13C NMR (75 MHz, 
Acetone-d6): δ 17.81, 22.16, 39.69, 111.35, 122.50, 
123.23, 125.64, 126.81, 127.75, 130.68, 132.25, 
134.37, 137.54; GC-MS: molecular ion (C19H19N5O) 
m/z value at 331.19. Anal. Calcd for C19H19N5O: С, 
68.45; Н, 5.74; N, 21.01. Found: С, 68.51; Н, 5.63; N, 
20.96%. Chiral HPLC: Column: Chiralpak IB column 
of diacel, Solvent system: DCM (20% 
ethanol)/Hexane 25: 75, Flow rate = 0.8 cc/min,  
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λ = 250 nm), tmajor= 13.57 min, tminor = 8.96 min,  
ee = 98%. 
N-(1-((1-(m-Tolyl)-1H-1,2,3-triazol-4-yl)methyl)-
(S)-(-)-2-(α-hydroxy ethyl) benzimidazole, 8c: Yield 
0.96 g (75%). m.p. 78°C. Specific rotation: [α]D25= 
+09° (c 1, Ethanol); 1H NMR (300 MHz, Acetone-d6): 
δ 1.76 (d, 3H, CH3, J = 4.8 Hz), 2.39 (s, 3H, CH3), 
5.43 (unresolved siglet, 1H), 5.74 (q, 2H), 7.19 (d, 
2H, J = 5.4 Hz), 7.26 (d, 2H, J = 7.8Hz), 7.39 (t,1H, J 
= 8.1 Hz), 7.59 (t, 2H, J = 8.4 Hz), 8.55 (s, 1H); 
13C NMR (75 MHz, Acetone-d6): δ 21.25, 110.20, 
118.23, 121.62, 123.31, 130.21, 130.46, 134.40, 
139.33; GC-MS: molecular ion (C19H19N5O) m/z 
value at 331.19. Anal. Calcd for C19H19N5O: С, 68.45; 
Н, 5.74; N, 21.01. Found: С, 68.37; Н,5.65; N, 
21.15%. Chiral HPLC: Column: Chiralpak IB column 
of diacel, Solvent system: DCM (20% 
ethanol)/Hexane 25:75, Flow rate = 0.8 cc/min,  
λ = 250 nm), tmajor = 12.55 min, tminor = 9.14 min,  
ee = 99%. 
N-(1-((1-(p-Tolyl)-1H-1,2,3-triazol-4-yl)methyl)-
(S)-(-)-2-(α-hydroxy ethyl) benzimidazole, 8d: 
Yield 1.04 g (81%). m.p. 103°C. Specific rotation: 
[α]25D = +22° (c 1, Ethanol); 1H NMR (300 MHz, 
Acetone-d6): δ 1.74 (d, 3H, CH3, J = 6Hz), 2.38 (s, 
3H, CH3), 5.03 (unresolved siglet,1H), 5.43 (s, 1H, 
OH), 5.73 (q, 2H, -CH2), 7.19 (s, 1H), 7.34 (d, 2H, 
J=7.2 Hz), 7.59 (d, 2H, J = 6.9 Hz), 7.67 (d, 2H, J = 
7.2 Hz), 8.53 (s, 1H); 13C NMR (75 MHz, Acetone-
d6): δ 20.94, 22.16, 39.66, 63.78, 111.25, 120.27, 
121.05, 122.15, 122.54, 123.23, 131.06, 136.52, 
139.65, 143.28, 145.17; GC-MS: molecular ion 
(C19H19N5O) m/z value at 331.13. Anal. Calcd for 
C19H19N5O: С, 68.45; Н, 5.74; N, 21.01. Found: С, 
68.40; Н, 5.47; N, 21.11%. Chiral HPLC: Column: 
Chiralpak IB column of diacel, Solvent system: DCM 
(20% ethanol)/Hexane 25:75, Flow rate = 0.8 cc/min, 
λ = 250 nm), tmajor = 17.41min, tminor = 14.75 min, ee = 
100%. 
N-(1-((1-(2-Methoxyphenyl)-1H-1,2,3-triazol-
4yl)methyl)-(S)-(-)-2-(α-hydroxyethyl) 
benzimidazole, 8e: Yield 0.84 g (66%). m.p. 60°C. 
Specific rotation: [α]25D= +24° (c 1, Ethanol); 
1H NMR (300 MHz, Acetone-d6): δ 1.761 (d, 3H, 
CH3, J = 5.1 Hz), 3.86 (s, 3H, CH3), 5.74 (q, 2H), 
7.08-7.19 (m, 2H), 7.20-7.65 (m, 7H, Ar), 8.45 (s, 
1H); 13C NMR (75 MHz, Acetone-d6): δ 56.51, 
113.64, 121.62, 121.80, 122.50, 123.21, 126.12, 
131.30, 143.77, 152.452; GC-MS: molecular ion 
(C19H19N5O2) m/z value at 347.1. Anal. Calcd for 
C19H19N5O2: С, 65.32; Н, 5.48; N, 20.04. Found: С, 
65.38; Н, 5.41; N, 20.13%. Chiral HPLC: Column: 
Chiralpak IB column of diacel, Solvent system: DCM 
(20% ethanol) /Hexane 25:75, Flow rate = 0.8 cc/min, 
λ = 250 nm), tmajor= 21.22 min, tminor = 12.50 min, ee = 
95%. 
Preparation of N-(1-((1-(4-methoxyphenyl)-1H-
1,2,3-triazol-4-yl)methyl)-(S)-(-)-2-(α-
hydroxyethyl) benzimidazole, 8f: Yield 1.06 g 
(83%). m.p. 89°C. Specific rotation: [α]25D = +16° (c 
1, Ethanol); 1H NMR (300 MHz, Acetone-d6): δ 1.744 
(d, 3H, CH3, J = 6.6 Hz), 3.85 (s, 3H, CH3), 5.42 (d, 
1H), 5.72 (q, 2H, J = 15.9 Hz), 7.05-7.23 (m, 4H), 
7.59-7.73 (m, 4H, Ar), 8.47 (s, 1H); 13C NMR (75 
MHz, Acetone-d6): δ 22.16, 39.65, 56.01, 63.76, 
111.25, 115.62, 120.29, 122.23, 122.51, 122.80, 
123.20, 145.04, 160.85; GC-MS: molecular ion 
(C19H19N5O2) m/z value at 347.1. Anal. Calcd for 
C19H19N5O2: С, 65.32; Н, 5.48; N, 20.04. Found: С, 
65.43; Н, 5.52; N, 20.06%. Chiral HPLC: Column: 
Chiralpak IB column of diacel, Solvent system: DCM 
(20% ethanol) /Hexane 25:75, Flow rate = 0.8 cc/min, 
λ = 250 nm), tmajor = 9.42 min, tminor = 14.64 min, ee = 
99%. 
N-1-((1-Phenyl-1H-1,2,3-triazol-4-yl)methyl)-
(S)-(+)-2-(α-hydroxybenzyl) benzimidazole (PT-
HBB), 8g: Yield 1.51 g (82%). m.p. 114°C. Specific 
rotation: [α]25D = +21° (c 1, Ethanol); 1H NMR (300 
MHz, CDCl3): δ 5.92 (s, 2H), 7.38-7.50 (m, 8H), 
7.52-7.70 (m, 3H), 7.90-7.97 (m, 2H), 8.373 (s, 1H), 
8.377 (d, 2H, J = 7.2Hz); 13C NMR (75 MHz, 
CDCl3): δ 29.68, 41.0, 111.76, 120.63, 121.75, 
122.01, 124.08, 128.45, 128.84, 129.68, 131.34, 
133.76, 135.91, 136.68, 136.94, 141.93, 144.33; GC-
MS: molecular ion (C16H16N2O) m/z value at 380.28. 
Anal. Calcd for C16H16N2O: С, 72.42; Н, 5.02; N, 
18.36. Found: С, 72.30; Н, 5.16; N, 18.27%. Chiral 
HPL: Column: Chiralpak IB column of diacel, 
Solvent system: DCM (20% ethanol) /Hexane 25:75, 
Flow rate = 0.5 cc/min, λ = 254 nm), tmajor =16.18 
min, tminor = 13.30 min, ee = 98%. 
N-1-((1-Phenyl-1H-1,2,3-triazol-4-yl)methyl)-
(S)-(-)-2-(α-acetoxy ethyl) benzimidazole (PT-
AEB), 9a: Yield 1.24 g (85%). m.p. 107°C. Specific 
rotation: [α]25D = −97° (c 1, Ethanol); 1H NMR (300 
MHz, CDCl3): δ 1.81 (d, 3H, J = 6.6 Hz), 2.039 (s, 
3H), 5.53 (d, 1H, J = 16.8Hz), 5.72 (d, 1H, J = 
16.8Hz), 6.26 (q, 1H, J = 6.6 Hz), 7.26-7.49 (m, 6H), 
7.62-7.7 (m, 2H), 7.78-7.9 (m, 2H); 13C NMR (75 
MHz, CDCl3): δ 19.35, 20.94, 39.53, 64.60, 109.93, 
SAPRE et al.: ENANTIOMERICALLY ENRICHED BENZIMIDAZOLE-TRIAZOLES 
 
 
99
120.24, 120.28, 120.48, 122.86, 123.63, 129.01, 
129.78, 134.65, 136.71, 142.16, 143.95, 152.32, 
170.48; GC-MS: molecular ion (C20H19N5O2) m/z 
value at 361.25. Anal. Calcd for C20H19N5O2: С, 
66.47; Н, 5.30; N, 19.38. Found: С, 66.53; Н, 5.19; N, 
19.47%. Chiral HPLC: Column: Chiralpak IB column 
of diacel, Solvent system: DCM (10% ethanol) 
/Hexane 25:75, Flow rate = 0.5cc/min, λ = 250 nm), 
tmajor = 26.42 min, tminor =14.95min, ee = 99%. 
N-(1-((1-(o-Tolyl)-1H-1,2,3-triazol-4-yl)methyl)-
(S)-(-)-2-(α-acetoxy ethyl) benzimidazole, 9b: Yield 
1.18 g (82%). m.p. 80°C. Specific rotation: [α]25D = 
−90° (c 1, Ethanol); 1H NMR (300 MHz, CDCl3): δ 
1.91 (d, 3H, J = 5.4Hz), 2.13 (s, 3H), 2.168 (s, 3H), 
5.60 (d, 1H, J = 15.9Hz), 5.80 (d, 1H, J = 14.7 Hz), 
6.30 (unresolved siglet, 1H), 7.16-7.26 (m, 6H), 7.28-
7.61 (m, 2H), 7.89 (s, 1H); 13C NMR (75 MHz, 
CDCl3): δ 17.80, 21.08, 39.79, 123.44, 124.23, 
125.86, 126.92, 130.14, 131.36, 131.58, 133.58, 
170.56; GC-MS: molecular ion (C21H21N5O2) m/z 
value at 375.21. Anal. Calcd for C21H21N5O2: С, 
67.18; Н, 5.64; N, 18.65. Found: С, 67.11; Н, 5.57; N, 
18.71%. Chiral HPLC: Column: Chiralpak IB column 
of diacel, Solvent system: DCM (10% ethanol) 
/Hexane 25:75, Flow rate = 0.5cc/min, λ = 250 nm), 
tmajor = 20.65min, tminor =12.74 min, ee = 99%. 
N-(1-((1-(m-Tolyl)-1H-1,2,3-triazol-4-yl)methyl)-
(S)-(-)-2-(α-acetoxy ethyl) benzimidazole, 9c: Yield 
1.22 g (84%). m.p. 72°C. Specific rotation: [α]25D = 
−86° (c 1, Ethanol); 1H NMR (300 MHz, CDCl3): δ 
1.84 (d, 3H, J = 6.6Hz), 2.09 (s, 3H), 2.39 (s, 3H), 
5.55 (d,1H, J = 16.8 Hz), 5.76 (d,1H, J = 14.7 Hz), 
6.28 (d,1H, J = 6.6 Hz), 7.26-7.34 (m, 6H), 7.50-7.53 
(d, 3H), 7.80 (s, 1H); 13C NMR (75 MHz, CDCl3): δ 
19.75, 21.08, 39.79, 110.20, 120.14, 120.45, 123.47, 
124.19, 130.31, 134.40, 139.33, 170.56; GC-MS: 
molecular ion (C21H21N5O2) m/z value at 375.20. 
Anal. Calcd for C21H21N5O2: С, 67.18; Н, 5.64; N, 
18.65. Found: С, 67.08; Н, 5.69; N, 18.75%. Chiral 
HPLC: Column: Chiralpak IB column of diacel, 
Solvent system: DCM (10% ethanol)/Hexane 25:75, 
Flow rate = 0.5cc/min, λ = 250 nm), tmajor = 24.45min, 
tminor =13.89 min, ee = 99%. 
N-(1-((1-(p-Tolyl)-1H-1,2,3-triazol-4-yl)methyl)-
(S)-(-)-2-(α-acetoxy ethyl) benzimidazole, 9d: Yield 
1.20 g (83%). m.p. 60°C. Specific rotation: [α]25D = 
−98° (c 1, Ethanol); 1H NMR (300 MHz, CDCl3): δ 
1.83 (d, 3H, J = 6.6Hz), 2.053 (s, 3H), 2.38 (s, 3H), 
5.57 (d,1H, J = 16.5 Hz), 5.77 (d, 1H, J = 16.5 Hz), 
6.29 (q, 1H, J = 6.6), 7.24-7.32 (m, 4H), 7.46-7.76 
(m, 2H), 7.87 (s, 1H), 7.88 (d,1H); 13C NMR (75 
MHz, CDCl3): δ 19.58, 21.04, 21.07, 39.80, 64.79, 
110.08, 120.26, 120.42, 123.16, 123.93, 125.84, 
130.00, 130.28, 134.39, 139.28, 141.70, 143.60, 
152.62, 170.46; GC-MS: molecular ion (C21H21N5O2) 
m/z value at 375.11. Anal. Calcd for C21H21N5O2: С, 
67.18; Н, 5.64; N, 18.65. Found: С, 67.14; Н, 5.52; N, 
18.60%. Chiral HPLC Column: Chiralpak IB column 
of diacel, Solvent system: DCM (10% 
ethanol)/Hexane 25:75, Flow rate = 0.5cc/min, λ = 
250 nm), tmajor = 25.92min, tminor =14.86 min, ee = 
96%. 
N-(1-((1-(2-Methoxyphenyl)-1H-1,2,3-triazol-4-
yl)methyl)-(S)-(-)-2-(α-acetoxyethyl) 
benzimidazole, 9e: Yield 1.16 g (80%). m.p. 80°C. 
Specific rotation: [α]25D = −88° (c 1, Ethanol); 
1H NMR (300 MHz, CDCl3): δ 1.84 (d, 3H, J = 6.0 
Hz), 2.07 (s, 3H), 3.75 (s, 3H), 5.65 (unresolved 
siglet, 1H), 5.80 (d, 1H, J = 16.8 Hz), 6.26 (q, 1H, J = 
6.6 Hz), 7.25-7.36 (m, 5H), 7.50-7.70 (m, 2H), 7.88 
(s, 1H); 13C NMR (75 MHz, CDCl3): δ 19.55, 20.99, 
39.88, 55.70, 64.81, 110.31, 120.18, 120.85, 123.17, 
123.91, 125.40, 130.44, 132.44, 151.04, 154.17, 
170.42; GC-MS: molecular ion (C21H21N5O3) m/z 
value at 391.14. Anal. Calcd for C21H21N5O2: С, 
64.44; Н, 5.41; N, 17.89. Found: С, 64.30; Н, 5.53; N, 
17.85%. Chiral HPLC: Column: Chiralpak IB column 
of diacel, Solvent system: DCM (10% 
ethanol)/Hexane25:75, Flow rate = 0.5cc/min, λ = 
250 nm), tmajor =29.68 min, tminor =15.59min, ee = 
99%. 
N-(1-((1-(4-Methoxyphenyl)-1H-1,2,3-triazol-4-
yl)methyl)-(S)-(-)-2-(α-hydroxyethyl) 
benzimidazole, 9f: Yield 1.26 g (87%). m.p. 91°C. 
Specific rotation: [α]25D = −102° (c 1, Ethanol); 
1H NMR (300 MHz, CDCl3): δ 1.87 (Unresolved 
Singlet, 3H), 2.101 (s, 3H), 3.83 (s, 3H), 5.66- 6.48 
(Unresovled aliphatic signals), 6.954-7.039 (m, 2H), 
7.34-7.93 (m, 7H); 13C NMR (75 MHz, CDCl3): δ 
21.04, 21.07, 39.80, 55.65, 114.57, 114.86, 122.22, 
124.35, 127.44, 160.11, 161.01, 170.52; GC-MS: 
molecular ion (C21H21N5O3) m/z value at 391.06. 
Anal. Calcdfor C21H21N5O3:С, 64.44; Н, 5.41; N, 
17.89. Found: С, 64.37; Н,5.36; N, 17.76%. Chiral 
HPLC: Column: Chiralpak IB column of diacel, 
Solvent system: DCM (10% ethanol) Hexane 25:75, 
Flow rate = 0.5cc/min, λ = 250 nm), tmajor = 22.76 
min, tminor =13.33 min, ee = 96%. 
N-1-((1-Phenyl-1H-1,2,3-triazol-4-yl)methyl)-
(S)-(-)-2-(α-acetoxybenzyl) benzimidazole (PT-
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ABB), 9g: Yield 1.51 g (76%). m.p. 121°C. Specific 
rotation: [α]25D = −45° (c 1, Ethanol); 1H NMR (300 
MHz, CDCl3): δ 2.21 (s, 3H), 5.91 (unresolved 
singlet, 2H), 6.12 (s, 1H), 7.00-7.56 (m, 7H), 7.62-
7.69 (m, 2H), 7.90-8.25 (m, 2H), 8.362 (s, 1H), 8.367 
(d, 2H, J = 7.2); 13C NMR (75 MHz, CDCl3): δ 40.99, 
111.76, 120.27, 120.62, 121.74, 122.0, 124.10, 126.0, 
126.35, 127.66, 128.36, 128.46, 128.86, 129.03, 
129.32, 129.69, 131.33, 133.79, 141.89; GC-MS: 
molecular ion (C25H21N5O2) m/z value at 423.17. 
Anal. Calcd for C25H21N5O2: С, 70.91; Н, 5.00; N, 
16.54. Found: С, 70.70; Н, 5.03; N, 16.60%. Chiral 
HPLC: Column: Chiralpak IB column of diacel, 
Solvent system: DCM (20% ethanol)/Hexane 25:75, 
Flow rate = 0.5 cc/min, λ = 254 nm), tmajor =26.94 
min, tminor =22.56 min, ee = 100%. 
 
Representative procedure for chiral base [PT-
HEB, 8a] mediated enantioselective Diels-Alder 
reactions 
To a 50 mL RBF containing PT-HEB 8a (10 mol 
%), anhydrous 1,2-Dichloroethane at -10°C, anthrone 
10 (97 mg, 0.5 mmol) and N-substituted maleimide 
11a-e (0.5 mmol) were added in this sequence. The 
reaction was carried out under dry condition and 
monitored with TLC. After stirring at −10°C for 8 h, 
on completion reaction mixture acidified with dilute 
hydrochloric acid and extracted with chloroform. The 
organic extracts were washed with brine, dried over 
sodium sulphate and filtered. The solvent was 
removed in vacuum, purified by using silica column 
chromatography (gradient elution with chloroform / 
pet. ether mixtures; 80:20). 
 
Characterization data of Diels-Alder adduct, 12a-e 
4-Hydroxy-2-methyl-3a,4,9,9a-tetrahydro-
4,9[1’,2’]-benzeno-1H-benz[f]isoindole-1,3(2H)-
dione, 12a: Yield 125.1 mg (86%). m.p. 218-220°C. 
Specific rotation:[α]25D = +44.1° (c 1, CHCl3); 
1H NMR (300 MHz, CDCl3): δ 2.49 (s, 3H), 3.11 (d, 
1H, J = 8.4 Hz), 3.32 (dd, 1H, J = 3.6, J = 8.5 Hz), 
4.42 (s, 1H), 4.72 (d, 1H, J = 3.3Hz), 7.10-7.34 (m, 
5H), 7.36 (m, 1H) 7.48 (m, 1H), 7.69 (m, 1H); GC-
MS:molecular ion (C19H15NO3) m/z value at 304.95; 
Chiral HPLC: Column: Chiralpak IB column of 
diacel, Solvent system: iPrOH/Hexane 10/90, Flow 
rate = 0.6 mL/min, λ = 230 nm, tmajor =23.28 min, 
tminor =19.59min, ee= 57%. 
Preparation of 4-hydroxy-2-ethyl-3a,4,9,9a-
tetrahydro-4,9[1’,2’]-benzeno-1H-benz[f]isoindole-
1,3(2H)-dione, 12b: Yield 130.7 mg (82%). m.p. 213-
215°C. Specific rotation:[α]25D =+33.7° (c 1, CHCl3); 
1H NMR (300 MHz, CDCl3): δ 0.40 (t, 3H, J = 7.2 
Hz), 3.07 (d, 1H, J = 8.7 Hz), 3.14 (q, 2H), 3.29 (dd, 
1H, J = 3.6 Hz, J = 8.5 Hz), 4.53 (s, 1H), 4.73 (d, 1H, 
J = 3.6 Hz), 7.13-7.27 (m, 5H), 7.36 (m, 1H), 7.50 (m, 
1H), 7.69 (m, 1H); GC-MS:molecular ion m/z value 
(C20H17NO3) at 318.96; Chiral HPLC: Column: 
Chiralpak AD column of diacel, Solvent system: 
iPrOH: Hexane 10:90, Flow rate = 0.6 mL/min, λ = 
230 nm, tmajor =26.84 min, tminor =24.07 min, ee= 83%. 
Preparation of 4-hydroxy-2-propyl-3a,4,9,9a-
tetrahydro-4,9[1’,2’]-benzeno-1H-benz[f]isoindole-
1,3(2H)-dione, 12c: Yield 139.81 mg (84%). m.p. 
208-210°C. Specific rotation:[α]25D =+ 5.7° (c 1, 
CHCl3);1H NMR (300 MHz, CDCl3): δ 0.54 (t, 3H, 
7.5 Hz), 0.79 (m, 2H), 3.01 (d, 1H), 3.08 (q, 2H), 3.29 
(dd, 1H, J = 3.6 Hz, J = 8.5Hz), 4.52 (s, 1H), 4.72 (d, 
1H, J = 3.6Hz), 7.13-7.27 (m, 5H), 7.34 (m, 1H), 7.50 
(m, 1H), 7.69 (m, 1H); GC-MS: molecular ion m/z 
value (C21H19NO3) at 333.38; Chiral HPLC: Column: 
Chiralpak IB column of diacel, Solvent system: 
iPrOH:Hexane 10:90, Flow rate = 0.6 mL/min, λ = 
230 nm, tmajor =20.07 min, tminor =15.71min, ee= 5%. 
Preparation of 4-hydroxy-2-butyl-3a,4,9,9a-
tetrahydro-4,9[1’,2’]-benzeno-1H-benz[f]isoindole-
1,3(2H)-dione, 12d: Yield142.2 mg (82%). m.p. 217-
219°C. Specific rotation:[α]25D = +12°(c 1, CHCl3); 
1H NMR (300 MHz, CDCl3):δ 1.14 (s, 9H), 2.95 (d, 
1H, J = 9.0 Hz), 3.17 (dd, 1H, J = 3.6 Hz, J = 9.0 Hz), 
4.69 (d, J = 3.6 Hz, 1H), 4.72 (s,1H), 7.17-7.27 (m, 
5H), 7.37 (dd, 1H,) 7.87 (m, 1H), 8.34 (m, 1H); GC-
MS:molecular ion (C22H21NO3) m/z value at 346.82; 
Chiral HPLC: Column: Chiralpak IB column of 
diacel, Solvent system: iPrOH/Hexane 10/90, Flow 
rate = 0.6 mL/min, λ = 230 nm, tmajor =16.28 min, 
tminor =10.79 min, ee= 28%. 
Preparation of 4-hydroxy-2-benzyl-3a,4,9,9a-
tetrahydro-4,9[1’,2’]-benzeno-1H-benz[f]isoindole-
1,3(2H)-dione, 12e: Yield142.8 mg (75%). m.p. 204-
207°C. Specific rotation:[α]25D =+36.5° (c 1, CHCl3); 
1H NMR (300 MHz, CDCl3): δ 3.23 (d, 1H, J = 8.7 
Hz), 3.40 (dd, 1H, J = 3.3, J = 8.1 Hz), 4.25 (s, 2H), 
4.56 (s, 1H), 4.71 (d, 1H, J = 3.3 Hz), 6.32 (m, 2H), 
7.03-7.21 (m, 8H), 7.40 (m, 1H), 7.49 (m, 1H), 7.587 
(m, 1H); GC-MS:molecular ion (C25H19NO3) m/z 
value at 380.86; Chiral HPLC: Column: Chiralpak IB 
column of diacel, Solvent system: iPrOH:Hexane 
20:80, Flow rate = 0.6 mL/min, λ = 230 nm, tmajor = 
21.16 min, tminor = 25.75 min, ee= 61%. 
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Conclusions 
An efficient Cu(I) catalysed procedure to 
synthesize benzimidazole based triazole tweezers has 
been developed. The compounds were obtained in 
highly enantiomerically enriched states and possess 
several structural features which are generally desired 
for an efficient chiral organo-catalysts and systems for 
exhibiting chiral molecular recognition. These 
tweezers 8a-f, 9a were shown to be potent chiral 
Brønsted base catalysts for Diels-Alder reaction of N-
substituted maleimides 11a-g and anthrone 10. Diels-
Alder adducts 12a-e with (S,S) configuration and 
moderate to good enantioselectivities were obtained. 
The developed enantioselective methodology for DA 
were more suitable for N-alkyl substituted maleimides 
giving good yields (75-86%) and moderate to 
excellent enantioselectivities (5-83% ee) while for 
aryl substituted maleimides 11f-g, no corresponding 
Diels-Alder adducts were obtained. 
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